

## Primary Hyperparathyroidism Committee meeting 3

**Date:** 02/11/2017

**Location:** NGC Boardroom

**Minutes:** Final

<b>Committee members present:</b>		
Jonathan Mant (Chair) (JM)		(Present for notes 1 – 5)
Terry Aspray (TA)		(Present for notes 1 – 5)
Julie Cox (JC)		(Present for notes 1 – 5)
Parijat De (PD)		(Present for notes 1 – 5)
Joy Foster (JF)		(Present for notes 1 – 5)
Imran Jawaid (IJ)		(Present for notes 1 – 5)
Fausto Palazzo (FP)		(Present for notes 1 – 5)
Peter Selby (PS)		(Present for notes 1 – 5)
Anthony Skene (AS)		(Present for notes 1 – 5)
Nicholas Thomson (NT)		(Present for notes 1 – 5)

<b>In attendance:</b>		
Andrew Harding (AH)	Guidelines Commissioning Manager, NICE	(Present for notes 1 – 5)
Judith McBride (JMB)	Senior Medical Editor, NICE	(Present for notes 1 – 5)
Emma Brockis (EB)	Senior Health Economist	(Present for notes 1 – 5)
Katie Broomfield (KB)	Document Editor/Process Assistant	(Present for notes 1 – 5)
Sharangini Rajesh (SR)	Research Fellow	(Present for notes 1 – 5)
Sharon Swain (SS)	Operations Director/Guideline Lead	(Present for notes 1 – 5)
Kyann Zhang (KZ)	Health Economist	(Present for notes 1 – 5)

<b>Apologies:</b>		
Jill Cobb	Information Specialist, NGC	
Meredith Faust (MF)	Project Manager, NGC	
Neil Gittoes (NG)	Guideline Committee member	
Jane Lynn (JL)	Business Analyst, NICE	

**1. Welcome and objectives for the meeting**

The Chair welcomed the Committee members and attendees to the third meeting on primary hyperparathyroidism. The Committee members and attendees introduced themselves.

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting.

**Introductions****2. Confirmation of matter under discussion, and declarations of interest**

The Chair asked everyone to declare verbally any interests that have arisen since application. The following new interests were received for this committee meeting:

**Committee Declarations of Interest**

N.B. The Chair and Committee members were recruited to this guideline using NICE DOI policy published Sept 2014.

<b>Insert initials</b>	<b>Declaration</b>	<b>Classification (as per the NICE DOI policy wording*)</b>	<b>Chair's action</b>
TA	Participation in a focus group discussion on osteoporosis, funded by UCB pharma. However, I am not aware of any drugs relevant to this guideline development.	Personal financial non-specific	Declare and participate

NICE DOI policy classifications are:

- Personal financial specific
- Personal financial non-specific
- Personal non-financial specific
- Personal non-financial non-specific
- Non-personal financial specific
- Non-personal financial non-specific

The DOI register was made available to the Committee chair. The chair reviewed the DOI register and deemed that none of the original DOIs were in conflict with the agenda topics and clinical questions under discussion at the meeting.

**3. Minutes of the last meeting**

The committee reviewed the minutes from the last meeting and agreed that they

were a true and accurate account of the meeting.

The Chair confirmed that all matters arising had been completed or were in hand.

#### **4. Presentations and discussion**

4.1 SS led a discussion on the rationale and impact write-up for the calcimimetics review.

4.2 SR gave a presentation on the clinical evidence for the surgery review. KZ gave a presentation on the unit costs for this review. The committee discussed the evidence.

4.3 JMB gave a presentation on NICE recommendations.

4.4 SS led a discussion on the approach for Q1.1, indications for testing.

4.5 SS and SR led a discussion on the draft protocols for monitoring, surgical interventions and diagnostic localisation.

#### **5. Any other business**

The group discussed next steps and agreed action points.

**Date of next meeting:** 01/12/2017

**Location of next meeting:** Sloane Room, Royal College of Physicians